Outrage over the Food and Drug Administration's recent approval of a new Alzheimer's treatment highlights several serious flaws in our nation's drug-approval process. We are focused on medical certainty, which can delay the availability of innovative, potentially life-saving treatments. Additionally, reports of behind-the-scenes machinations are creating authentically earned distrust in the products manufactured by our pharmaceutical industry, which leads the world in innovation.
